XLO - Xilio Therapeutics Inc
IEX Last Trade
0.8604
0.057 6.602%
Share volume: 364,235
Last Updated: Fri 30 Aug 2024 09:55:28 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.80
0.06
7.07%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-4.92%
1 Month
-10.64%
3 Months
-7.76%
6 Months
29.98%
1 Year
-70.21%
2 Year
-61.70%
Key data
Stock price
$0.86
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.49 - $2.90
52 WEEK CHANGE
-$0.70
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: xiliotx.com
Employees: 112
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: xiliotx.com
Employees: 112
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. to learn more, please visit www.xiliotx.com.
Recent news